NEJMÊÙ¶¯²ñ2003 Âè6²ó03/02/26 ¼Â»Ü A¥×¥ê¥ó¥È ôÅö: ¿¹Àî ¿¿Âç (morikawa-tky@umin.ac.jp) Case 2-2003: A 60-Year-Old Man with Mild Congestive Heart Failure of Uncertain Cause ¡ÊVolume 348(3): 243-249¡Ë
¡Ú´µ¼Ô¡Û 60ºÐÃËÀ ¡Ú¼çÁÊ¡Û ¸ÆµÛº¤Æñ¡¤ÇÙݵ·ì ¡Ú¸½ÉÂÎò¡Û ȯ¾ÉÁ°¤Þ¤Ç¡¤´µ¼Ô¤Ï·ò¹¯¤Ç¤¢¤Ã¤¿¡¥ Æþ±¡¤Î7ÆüÁ°¡¤ÃæÅùÅ٤α¿Æ°¤ò¤·¤¿»þ¤Ë¸ÆµÛº¤Æñ¤ò´¶¤¸¤¿¡¥ Æþ±¡¤Î4ÆüÁ°¡¤¹ø¤ò¶Ê¤²¤ÆÁ°¤«¤¬¤ß¤Ë¤Ê¤Ã¤¿¤êû¤¤µ÷Î¥¤òÊ⤤¤¿»þ¤Ë¡¤Êü»¶¤·¤Ê¤¤¡¤"½Å¤¤"ÉÔ²÷´¶¤ò¶»¹ü¸åÉô¤È¾åÊ¢Éô¤Ë¼«³Ð¤¹¤ë¤è¤¦¤Ë¤Ê¤Ã¤¿¡¥µ¯ºÂ¸ÆµÛ¡¤È¯´À¡¤°¿´¡¤Éâ¼ð¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥ Æþ±¡¤Î2ÆüÁ°¡¤´µ¼Ô¤Ï¾±¡¤ËÆþ±¡¤·¤¿¡¥BP 150/70 mmHg¡¤PR 80-90 /min irreg.¡¤Ä°¿Ç¾åξ¦ÇÙÄìÉô¤ÇµÛµ¤»þ¤Îcrackle¡¤¿´²»¤Ç¤ÏµÅÙ¤Îsystolic murmur¤¬Ä°¼è¤µ¤ì¤¿¡¥Ê¢Éô¤Ë¤Ï°Û¾ï¤Ê¤¯¡¤Ëö¾¿¤ÎÉâ¼ð¤âǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥¸¡ººÃÍ(Table 1¤ÈTable 2¤ò»²¾È)¤Ç¤Ï¡¤CK¡¤CK-MB¡¤troponin¤¬¤½¤ÎÆü¤Î2Å٤θ¡ºº¤ÇÀµ¾ïÈÏ°ÏÆâ¤Ç¤¢¤Ã¤¿¡¥¤½¤Î¾¡¤BUN¡¤Cre¡¤Glu¡¤Ca¡¤Mg¡¤ÅŲò¼Á¡¤AST (GOT)¡¤ALT (GPT)¡¤ALP¤ÏÀµ¾ïÈÏ°ÏÆâ¤Ç¤¢¤Ã¤¿¡¥ECG¾åAF¡¤¹âÅÙAV block¡¤¿´¼¼À´ü³°¼ý½Ì¡¤V1-V4¤ÇRÇÈȯ°é¤ÎÃÙ±ä(delayed R-wave progression)¤¬Ç§¤á¤é¤ì¤¿¤¬¡¤°Û¾ïQÇȤäÈóÆðÛŪST-TÊѲ½¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥CXR¤Ç¤Ï¿´³ÈÂç¤È²¼Íդο»½á±Æ¤¬Ç§¤á¤é¤ì¡¤Ýµ·ìÀ¿´ÉÔÁ´¤ò¼¨º¶¤¹¤ë½ê¸«¤Ç¤¢¤Ã¤¿¡¥FurosemideÀÅÃí¤Ë¤ÆÍøÇ¢¤¬ÆÀ¤é¤ì¡¤¶»¹ü¸åÉô¤È¾åÊ¢Éô¤ÎÉÔ²÷´¶¤Ï¾Ã»¶¤·¤¿¡¥ ¾±¡Æþ±¡2ÆüÌÜ(MGHÆþ±¡ÅöÆü)¤ËºÆÅٻܹԤ·¤¿ECG¤Ë¤Æaf¡¤HR 48-55 bpm¡¤¤ï¤º¤«¤ÊTÇȤÎÊѲ½¤¬Ç§¤á¤é¤ì¤¿¡¥´µ¼Ô¤Ï6ǯ´Ödigoxin¤òÉþÍѤ·¤Æ¤¤¤¿¤¬¡¤¤³¤Î»þÅÀ¤Ç°ì»þÃæÃǤ·¤¿¡¥¤½¤ÎÆü¤ÎͼÊý¡¤´µ¼Ô¤ÏMGH¤ËÈÂÁ÷¤µ¤ìÆþ±¡¤·¤¿¡¥ÈÂÁ÷»þ¤Ë¤Ïverapamil¡¤furosemide¡¤enteric-coated aspirin¡¤K À½ºÞ¡¤prednisone¤òÉþÍѤ·¤Æ¤¤¤¿¡¥ ¡Ú´û±ýÎò¡Û ¡¦ ¹â·ì°µ: verapamil (240mg/day)¤Ë¤Æ¥³¥ó¥È¥í¡¼¥ëÃæ ¡¦ ¶»ÄË(6ǯÁ°): ÈóÄ귿Ū¶»Äˤ¬Ç§¤á¤é¤ì¤¿¤¿¤áÉé²Ù»î¸³¤ò¹Ô¤Ã¤Æ¤¤¤ë¡¥°ì»þŪ¤Ësupraventricular tachycardia¤¬Ç§¤á¤é¤ì¤¿¤¬¡¤¤½¤ì°Ê³°¤Ë¤Ï°Û¾ï¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥¤½¤Î»þ¤«¤édigoxin¤¬³«»Ï¤µ¤ì¤¿¡¥Æ±Ç¯¿´¥¨¥³¡¼¤¬»Ü¹Ô¤µ¤ì¡¤º¸Ë¼¤Î·ÚÅÙ³ÈÂç(45 mm)¡¤ÂçÆ°Ì®´ðÉô¤Î·ÚÅÙ³ÈÂç(AR(-))¡¤·ÚÅÙ¤ÎPR¤¬Ç§¤á¤é¤ì¤¿¡¥Æþ±¡¤Î2ǯÁ°¤ËºÆÅÙÉé²Ù»î¸³¤ò¹Ô¤Ã¤¿¤¬¡¤°Û¾ï¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥Æþ±¡¤Î1ǯÁ°¤Ë¡¤af¤¬µ¯¤³¤Ã¤¿¤¬¼«Á³¾Ã¼º¤·¤¿¡¤¤È¤¤¤¦¥¨¥Ô¥½¡¼¥É¤¬¤¢¤Ã¤¿¡¥ ¡¦ ÈèÏ«´¶(¿ôǯÁ°¤«¤é), ¸ÆµÛº¤Æñ(5ǯÁ°¤«¤é): ¼ó¤Î¤à¤¯¤ß¡¤È¯ºîÀÌë´Ö¸ÆµÛº¤Æñ¡¤Æ°Ø©¤òȼ¤¦¡¥ ¡¦ ËýÀ´ØÀá¥ê¥¦¥Þ¥Á: prednisone (5 mg/day)¡¤methotrexate¤òĹǯÉþÍÑ¡¥Æþ±¡¤Î6¥ö·îÁ°¤«¤é¡¤methotrexate¤òetanercept (TNF-¦ÁÁ˳²ºÞ)¤ËÊѤ¨¤¿¡¥¼ê»Ø¤Î秤òÃÇÎö¤·¤¿¤³¤È¤¬¤¢¤ë¤¬¡¤¼ê½ÑŪ¤Ë¼£ÎŤµ¤ì¤¿¡¥¸½ºß¡¤º¸¼ê´ØÀá¤ÎÊÑ·Á¤ËÂФ·¤Æ¼ê½ÑÂÔ¤Á¤Î¾õÂ֤Ǥ¢¤ë¡¥ ¡Ú´§´í¸±°ø»Ò¡Û positive RFs; age>45yrs, male, ex-smoker(+), hypertension(+), low HDL-C(+) negative RFs; hyper lipidemia(-), diabetes mellitus(-), family history of heart disease(-) ¡Ú¿¦¶ÈÎò¡Û sales manager ¡ÚÀ¸³èÎò¡Û alcohol: µ¡²ñ°û¼ò, cigarettes: ex-smoker (¡Ö¿ôǯÁ°¤Ë¤ä¤á¤¿¡×) ¡ÚÆþ±¡»þ¸½¾É¡Û <VITAL SIGNS> BT 36.9 ¡î, BP 165/85 mmHg, PR 82 /min irreg., RR 20 /min <FACE> ruddy, telangiectases <NECK> jugular venous pulse: 10 cm above sternal notch <LUNG> lung sound: crackles at the lung bases <HEART> apical systolic murmur (Levine µ/º), early diastolic sound <ABDOMEN> n.p. <VASCULATURE> femoral (++/++), popliteal (trace/trace), posterior tibilal (+/+), dorsalis pedis (++/++) <EXTREMITIES> edema (¡Þ), rheumatoid deformities: most prominent in the hands, synovitis (-) ¡ÚÆþ±¡»þ¸¡ºº½ê¸«¡Û(Table 1¤ÈTable 2¤ò»²¾È) <CBC> WBC 8.7¡ß103/mm3 (Neu 76 %, Eos 2 %, Baso 1 %, Mono 4%, Lym 17 %), Ht 40.9% (MCV 85 ¦Ìm3), Plt 13.8¡ß104/mm3 <CHEMISTRY> TP 8.6 g/dl, Alb 4.1 g/dl, LDH 261 IU/l, T.Bil 1.5 mg/dl, D.Bil 0.3 mg/dl, BUN: w.n.l., Cre: w.n.l., Na 138 mEq/l, K 3.2 mEq/l, Cl 99 mEq/l, T.chol 134 mg/dl, HDL-Chol 28 mg/dl, LDL-Chol 88 mg/dl, TG 90 mg/dl, Glu: w.n.l., RF 319 IU/ml <COAGULATION> PT 15 sec., PTT: w.n.l. <DRUGS> digoxin 0.7 ng/ml <ECG> HR 74 bpm, AF (4:1 conduction), diffuse ST segment and T-wave abnormalities <Spirography> (Table 3¤ò»²¾È) <CXR> CTR: upper limit of the normal range, lung fields: bilateral air-space disease, pleural effusion (+) <UCG> IVSth 11 mm, LVDd/Ds w.n.l., EF 64 %, AoD 31 mm, LAD slightly enlarged, pericardial effusion (-) Doppler: Mr trivial, mitral E-wave DT: 135 msec, IRT: 80 msec, pulmonary venous diastolic inflow velocity: 100 cm/sec, phasic variation in the transmitral flow velocity with breathing: (-) ¡ÚÆþ±¡¸å·Ð²á¡Û ·Ð¶»ÊÉ¿´¥¨¥³¡¼¤ò»Ü¹Ô¤·¤¿¡¥º¸¼¼¤Î¥µ¥¤¥º¤Ë°Û¾ï¤Ï¤Ê¤¯¡¤Êɱ¿Æ°¤Ë¤â°Û¾ï¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥DopplerË¡¤Ë¤ÆÁÎ˹ÊÛ¸ýÉô·ìή®ÅÙ¤ÈÇÙÀÅ̮ήÆþ®ÅÙ¤ò·×¬¤·¤¿¤È¤³¤í¡¤³ÈÄ¥Áá´ü·ìή¤ÎµÞ½Ô¤ÊΩ¤Á¾å¤¬¤ê¤¬Ç§¤á¤é¤ì¡¤¤Þ¤¿º¸Ë¼°µ¤Î¾å¾º¤¬ÌÀ¤é¤«¤Ë¤Ê¤Ã¤¿¡¥³ÈÄ¥Áá´üÇÈ(EÇÈ)¤Î¥Ô¡¼¥¯Î®Â®¤Ï160 cm/sec¤ÈÁý¹â¡¤EÇȤθºÂ®»þ´Ö(deceleration time: DT)¤Ï135 msec¤Èû½Ì¤·¤Æ¤¤¤¿¡¥º¸¼¼ÅùÍÆÃд˴ü(isovolumic relaxation time: IRT)¤Ï80 msec¤ÇÀµ¾ïÈÏ°ÏÆâ¡¥ÇÙÀÅÌ®³ÈÄ¥´üήÆþ®ÅÙ¤Ï100 cm/sec¤Ç¤¢¤Ã¤¿¡¥ÂçÆ°Ì®Êۤϲò˶³ØŪ¡¤µ¡Ç½Åª¤ËÀµ¾ï¤À¤Ã¤¿¡¥ÁÎ˹ÊÛ¸ýÉô·ìή®Å٤θƵÛÀÊÑÆ°¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥±¦Ë¼¤â¥µ¥¤¥º¡¤µ¡Ç½Åª¤ËÀµ¾ï¡¥±¦Ë¼°µ¤ò10 mmHg¤È²¾Äꤷ¤¿¤È¤¤Ë¡¤±¦¼¼¼ý½Ì´ü°µ¤Ï35 mmHg¤È¿äÄꤵ¤ì¤¿¡¥¿´Ëì±Õ¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡¥ (ÊÌ»æ¤È¤·¤ÆÇۤä¿»²¹Í¥×¥ê¥ó¥È) ¤¢¤ë¿ÇÃÇŪ¼êµ»¤¬»Ü¹Ô¤µ¤ì¤¿¡¥ |